Multidisciplinary consensus on sputum induction biosafety during the COVID‐19 pandemic

Crespo‐Lessmann, Astrid; Plaza, Vicente; Almonacid, Carlos; Caballero, María Luisa; Cañas, J. A.; Gracia, J.; Cruz, María Jesús; Rivas, David Dacal; Muñiz, María del Camino; Llano, Luis Pérez del; Pozo, Victoria del; Carrasco, Valentín López; Trigo, José María Marín; Mateus, Eder; Muñoz, Xavier; Olaguibel, JM; Quirce, Santiago; Ramos, David; Sanz-Rubio, David; Sastre, Joaquı́n; Martín, Silvia Vázquez; Solsona, Elisabet Vera

doi:10.1111/all.14697

Cited by 14 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sputum induction is the gold standard approach to the non‐invasive study of airway inflammation. A consensus‐based protocol to ensure its biosafety in clinical practice during the current COVID‐19 pandemic was recently published 131 …”

Section: Asthma and Covid‐19 Pandemicsmentioning

confidence: 99%

Advances and highlights in asthma in 2021

Agache

Eguiluz‐Gracia

Cojanu

et al. 2021

Allergy

103

View full text Add to dashboard Cite

Last year brought a significant advance in asthma management, unyielding to the pressure of the pandemics. Novel key findings in asthma pathogenesis focus on the resident cell compartment, epigenetics and the innate immune system. The precision immunology unbiased approach was supplemented with novel tools and greatly facilitated by the use of artificial intelligence. Several randomised clinical trials and good quality realworld evidence shed new light on asthma treatment and supported the revision of several asthma guidelines (GINA, Expert Panel Report 3, ERS/ATS guidelines on severe asthma) and the conception of new ones (EAACI Guidelines for the use of biologicals in severe asthma). Integrating asthma management within the broader context of Planetary Health has been put forward. In this review, recently published articles and clinical trials are summarised and discussed with the goal to provide clinicians and researchers with a concise update on asthma research from a translational perspective.

show abstract

Section: Asthma and Covid‐19 Pandemicsmentioning

confidence: 99%

Advances and highlights in asthma in 2021

Agache

Eguiluz‐Gracia

Cojanu

et al. 2021

Allergy

103

View full text Add to dashboard Cite

show abstract

“…In this case, the medical protocols were adapted to guarantee the safety of the patients and healthcare professionals, such as the use of personal protection equipment, and alternative sampling and processing procedures. 86 EAACI launched a series of statements and position papers providing official recommendations for the treatment of drug hypersensitivity, allergic rhinitis, asthma, and other allergic diseases during the COVID-19 pandemic (Table 1) 14,87,89-92 . It also offered…”

Section: Allergy Care Does Not Stop During Covid-19mentioning

confidence: 99%

“…As sputum induction generates aerosols it presents a high risk of viral transmission. In this case, the medical protocols were adapted to guarantee the safety of the patients and healthcare professionals, such as the use of personal protection equipment, and alternative sampling and processing procedures 86 …”

Section: Allergy Care Does Not Stop During Covid‐19mentioning

confidence: 99%

Recent advances and developments in COVID‐19 in the context of allergic diseases

Ding

Sun

Sokołowska

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.

show abstract

“…The use of aerosol‐generating procedures such as OAC, spirometry, and IS testing has been restricted due to the risk of virus transmission. As the pandemic was not likely to stop, the authors of guidelines focused on how to safely perform some of these procedures, 17 and an urgent need emerged to develop tools for the diagnosis of aspirin hypersensitivity based on clinical data that are easy to obtain during the pandemic. Recently, it was shown that an informatics algorithm based on electronic health records datasets including inflammatory biomarkers, could successfully identify, with a high positive predictive value, both known and previously undiagnosed cases of NERD 18 .…”

Section: Discussionmentioning

confidence: 99%

Machine learning in the diagnosis of asthma phenotypes during coronavirus disease 2019 pandemic

Gawlewicz‐Mroczka

Pytlewski

Celejewska‐Wójcik

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Background During the coronavirus disease 2019 (COVID‐19) pandemic, it has become a pressing need to be able to diagnose aspirin hypersensitivity in patients with asthma without the need to use oral aspirin challenge (OAC) testing. OAC is time consuming and is associated with the risk of severe hypersensitive reactions. In this study, we sought to investigate whether machine learning (ML) based on some clinical and laboratory procedures performed during the pandemic might be used for discriminating between patients with aspirin hypersensitivity and those with aspirin‐tolerant asthma. Methods We used a prospective database of 135 patients with non‐steroidal anti‐inflammatory drug (NSAID)–exacerbated respiratory disease (NERD) and 81 NSAID‐tolerant (NTA) patients with asthma who underwent OAC. Clinical characteristics, inflammatory phenotypes based on sputum cells, as well as eicosanoid levels in induced sputum supernatant and urine were extracted for the purpose of applying ML techniques. Results The overall best ML model, neural network (NN), trained on a set of best features, achieved a sensitivity of 95% and a specificity of 76% for diagnosing NERD. The 3 promising models (i.e., multiple logistic regression, support vector machine, and NN) trained on a set of easy‐to‐obtain features including only clinical characteristics and laboratory data achieved a sensitivity of 97% and a specificity of 67%. Conclusions ML techniques are becoming a promising tool for discriminating between patients with NERD and NTA. The models are easy to use, safe, and achieve very good results, which is particularly important during the COVID‐19 pandemic.

show abstract

Multidisciplinary consensus on sputum induction biosafety during the COVID‐19 pandemic

Cited by 14 publications

References 31 publications

Advances and highlights in asthma in 2021

Advances and highlights in asthma in 2021

Recent advances and developments in COVID‐19 in the context of allergic diseases

Machine learning in the diagnosis of asthma phenotypes during coronavirus disease 2019 pandemic

Contact Info

Product

Resources

About